BridgeMD
New treatment option for Polycystic Ovary Syndrome (PCOS)
Official title Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)
ClinicalTrials.gov ID: NCT07298564
What this study is testing
- What it's testing
- Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age and is associated with metabolic abnormalities such as insulin resistance, dyslipidemia, and hormonal imbalance, which may lead to infertility and hirsutism. Despite the availability of several pharmacological treatments, many therapies fail to effectively address the underlying metabolic and endocrine dysfunctions of PCOS.
- Time commitment: about 12 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 65, women only
You may be able to join if
- Age between 19 and 65 years.
- Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.
You likely can't join if
- Hypothyroidism
- Menopause
- Pregnancy or breastfeeding
- Renal (kidney) dysfunction
- Use of therapeutic vitamin or mineral supplements
- Liver diseases (e.g., grade 3 fatty liver, hepatitis, or cirrhosis)
See the full eligibility criteria
- Age between 19 and 65 years.
- Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.
- Hypothyroidism
- Menopause
- Pregnancy or breastfeeding
- Renal (kidney) dysfunction
- Use of therapeutic vitamin or mineral supplements
- Liver diseases (e.g., grade 3 fatty liver, hepatitis, or cirrhosis)
- Psychiatric disorders such as bipolar disorder
- Neuromuscular diseases (e.g., myasthenia gravis, Parkinson's disease, multiple sclerosis, epilepsy, or muscular dystrophy)
- History of seizures
- Participants who become pregnant during the study or fail to comply with more than 20% of the study protocol will be withdrawn from the study
The study team makes the final eligibility decision.
Where it's taking place
- Tehran, Tehran Province, Iran
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling female, 19 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tehran, Tehran Province, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.